Scarica l'app Stockscreener
1.73
0.57%
-0.01
Dopo l'orario di chiusura:
1.72
-0.01
-0.58%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CHRS Giù?
Forum
Previsione
Coherus Oncology Inc Borsa (CHRS) Ultime notizie
Coherus Biosciences (CHRS) is one of the best penny stocks, here is why - MSN
Coherus Oncology (NASDAQ:CHRS) Stock Price Passes Above 200 Day Moving AverageShould You Sell? - MarketBeat
Why The Coherus Oncology (CHRS) Story Is Shifting Around Growth Assumptions And Execution Risk - Yahoo Finance
Coherus Biosciences (CHRS) Is One of the Best Penny Stocks, Here is Why - Yahoo Finance
Coherus Oncology (CHRS) upgraded to buy: Here's what you should know - msn.com
Vanguard disaggregates holdings; 0% stake in Coherus (NASDAQ: CHRS) - Stock Titan
If You Invested $1,000 in Coherus (CHRS) - Stock Titan
Metastatic Hepatocellular Carcinoma Clinical Trial Pipeline - openpr.com
Coherus Oncology (CHRS) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Coherus Oncology (NASDAQ:CHRS) Shares Pass Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Is Biodesix (BDSX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Coherus Oncology announces proposed public offering of common stock - MSN
CHRS Technical Analysis & Stock Price Forecast - Intellectia AI
Coherus BioSciences Q4 2025 earnings preview - MSN
Coherus Oncology (CHRS) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
Coherus Oncology Pivots to Immuno-Oncology, Touts LOQTORZI Growth and New Pipeline at Citizens Conf. - MarketBeat
Coherus Oncology (NASDAQ:CHRS) Upgraded at Wall Street Zen - MarketBeat
Coherus Oncology, Inc. (NASDAQ:CHRS) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Coherus Oncology (CHRS) price target increased by 13.33% to 5.78 - MSN
Coherus Oncology (CHRS) Revenue Gains Contrast With Persistent US$46 Million Quarterly Losses - Sahm
Coherus outlines $175M annualized LOQTORZI target by 2028 as commercial expansion accelerates - MSN
Coherus BioSciences at The Citizens Conference: Strategic Oncology Shift By Investing.com - Investing.com Canada
CHRS: Rapid oncology pipeline progress and strong LOQTORZI sales drive growth and pivotal trial plans - TradingView
Coherus Oncology Doubles LOQTORZI Revenue in 2025, Advances Oncology Pipeline and Significantly Reduces Debt 1 - Minichart
Oppenheimer reiterates Coherus Biosciences stock rating at Outperform By Investing.com - Investing.com India
Oppenheimer reiterates Coherus Biosciences stock rating at Outperform - Investing.com
Coherus Oncology, Inc. 2025 Annual Report – LOQTORZI Sales Growth, Pipeline Advances, and Strategic Shift to Immuno-Oncology - Minichart
Coherus Oncology Inc (CHRS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Coherus Oncology Q4 2025 Earnings Call Transcript - MarketBeat
Coherus Oncology Inc (CHRS) Q4 2025 Earnings Call Highlights: St - GuruFocus
Coherus Oncology (CHRS) Sees Strong Growth with LOQTORZI - gurufocus.com
Coherus Oncology Reports Q4 Earnings Loss - National Today
Coherus Oncology Q4 Earnings Call Highlights - MarketBeat
CHRS: LOQTORZI sales doubled, debt slashed, and key oncology trials advance toward 2026 data - TradingView
CHRS: LOQTORZI revenue doubled, debt slashed, and pipeline advances set up major 2026 milestones - TradingView
CHRS Q4 Revenue Falls Short but Strategic Shift Shows Promise - GuruFocus
Coherus Oncology Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Coherus Oncology (CHRS) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Coherus Oncology Q4 2025 Results: Quarterly Loss, Annual ProfitNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Coherus Oncology: Fourth Quarter Financial Results Overview - Bitget
Coherus Oncology (NASDAQ:CHRS) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Coherus Oncology (NASDAQ: CHRS) reports 2025 results and sharp debt cut - Stock Titan
Coherus Oncology: Q4 Earnings Snapshot - Barchart.com
Coherus Oncology Q4 revenue misses estimates - TradingView
Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update - The Manila Times
BRIEF-Coherus Oncology Q4 Sales USD 12.748 Million Vs. IBES Estimate USD 13.9 Million - TradingView
Cancer drug LOQTORZI sales double to $40.8M as trials near - Stock Titan
Coherus BioSciences (CHRS) Q4 Earnings Preview: What to Expect - GuruFocus
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):